肾移植受者合并新型冠状病毒感染的诊疗进展  

Progress in diagnosis and treatment of SARS-CoV-2 infection in kidney transplant recipients

作　　者：吴凯军 陈代晖 李茂[1] 梁思敏[1] WU Kai-jun;CHEN Dai-hui;LI Mao;LIANG Si-min(Department of Urology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院泌尿外科,重庆400016

出　　处：《局解手术学杂志》2025年第4期354-357,共4页Journal of Regional Anatomy and Operative Surgery

基　　金：重庆医科大学附属第一医院学科提升培育项目(2-01-02-03-XKTS1160)。

摘　　要：自2019年12月新型冠状病毒肺炎(COVID-19)疫情爆发以来,不断发生变异的新型冠状病毒(SARS-CoV-2)给实体器官移植领域带来了前所未有的挑战。而肾移植受者(KTRs)由于常年服用免疫抑制剂及合并多种合并症,是SARS-CoV-2感染后进展为重症的高危人群。本文旨在结合当前新的流行病学背景,对肾移植工作的最新诊疗进展进行综述,为后续新的流行病学背景下KTRs的管理提供参考。Since the outbreak of novel coronavirus pneumonia(COVID-19)in December 2019,SARS-CoV-2,which is constantly mutating,has brought unprecedented challenges to the field of solid organ transplantation.However,kidney transplant recipients(KTRs)are at high risk of developing severe disease after SARS-CoV-2 infection due to years of immunosuppressants and a variety of complications.This article aims to review the latest diagnosis and treatment progress of kidney transplantation under the current new epidemiological background,so as to provide reference for the subsequent management of KTRs under the new epidemiological background.

关 键 词：新型冠状病毒 Omicron变异株 肾移植 

分 类 号：R692.5[医药卫生—泌尿科学]